Coselli Joseph S, Volguina Irina V, LeMaire Scott A, Connolly Heidi M, Sundt Thoralf M, Milewicz Dianna M, Dietz Harry C, Amarasekara Hiruni S, Green Susan Y, Zhang Qianzi, Schaff Hartzell V, Miller D Craig
Division of Cardiothoracic Surgery, Michael E. DeBakey Department of Surgery, Baylor College of Medicine, Houston, Tex; Section of Adult Cardiac Surgery, Department of Cardiovascular Surgery, Texas Heart Institute, Houston, Tex; CHI St Luke's Health-Baylor St Luke's Medical Center, Houston, Tex; Cardiovascular Research Institute, Baylor College of Medicine, Houston, Tex.
Division of Cardiothoracic Surgery, Michael E. DeBakey Department of Surgery, Baylor College of Medicine, Houston, Tex; Office of Surgical Research, Michael E. DeBakey Department of Surgery, Baylor College of Medicine, Houston, Tex.
J Thorac Cardiovasc Surg. 2023 May;165(5):1790-1799.e12. doi: 10.1016/j.jtcvs.2021.08.064. Epub 2021 Sep 4.
The objective of this study was to compare midterm outcomes of aortic valve-replacing root replacement (AVR) and aortic valve-sparing root replacement (AVS) operations in patients with Marfan syndrome.
Patients who met strict Ghent diagnostic criteria for Marfan syndrome and who underwent either AVR or AVS between March 1, 2005 and December 31, 2010 were enrolled in a 3-year follow-up prospective, multicenter, international registry study; the study was subsequently amended to include 20-year follow-up. Enrollees were followed clinically and echocardiographically.
Of the 316 patients enrolled, 77 underwent AVR and 239 underwent AVS; 214 gave reconsent for 20-year follow-up. The median clinical follow-up time for surviving patients was 64 months (interquartile range, 42-66 months). Survival rates for the AVR and AVS groups were similar at 88.2% ± 4.4% and 95.0% ± 1.5%, respectively (P = .1). Propensity score-adjusted competing risk modeling showed associations between AVS and higher cumulative incidences of major adverse valve-related events, valve-related morbidity, combined structural valve deterioration and nonstructural valve dysfunction, and aortic regurgitation ≥2+ (all P < .01). No differences were found for reintervention (P = .7), bleeding (P = .2), embolism (P = .3), or valve-related mortality (P = .8).
Five years postoperatively, major adverse valve-related events and valve-related morbidity were more frequent after AVS than after AVR procedures, primarily because of more frequent aortic valve dysfunction. No between-group differences were found in rates of survival, valve-related mortality, reintervention on the aortic valve, or bleeding. We plan to follow this homogenous cohort for 20 years after aortic root replacement.
本研究旨在比较马方综合征患者行主动脉瓣置换根部置换术(AVR)和保留主动脉瓣根部置换术(AVS)的中期疗效。
符合马方综合征严格根特诊断标准且在2005年3月1日至2010年12月31日期间接受AVR或AVS手术的患者被纳入一项为期3年的随访前瞻性、多中心、国际注册研究;该研究随后修订为包括20年随访。对入组者进行临床和超声心动图随访。
在316例入组患者中,77例行AVR,239例行AVS;214例再次同意进行20年随访。存活患者的中位临床随访时间为64个月(四分位间距,42 - 66个月)。AVR组和AVS组的生存率相似,分别为88.2%±4.4%和95.0%±1.5%(P = 0.1)。倾向评分调整的竞争风险模型显示,AVS与主要不良瓣膜相关事件、瓣膜相关发病率、结构性瓣膜退变和非结构性瓣膜功能障碍合并症以及主动脉反流≥2+的累积发生率较高相关(所有P < 0.01)。在再次干预(P = 0.7)、出血(P = 0.2)、栓塞(P = 0.3)或瓣膜相关死亡率(P = 0.8)方面未发现差异。
术后5年,AVS术后主要不良瓣膜相关事件和瓣膜相关发病率比AVR术后更频繁,主要原因是主动脉瓣功能障碍更频繁。在生存率、瓣膜相关死亡率、主动脉瓣再次干预率或出血率方面未发现组间差异。我们计划在主动脉根部置换术后对这一同质队列进行20年随访。